Clovis Oncology Stock News

During the last session, Clovis Oncology Inc. (NASDAQ:CLVS)’s traded shares were 4.05 million, with the beta value of the company hitting 1.71. At the end of the trading day, the stock’s price was $1.74, reflecting an intraday gain of 10.83% or $0.17. The 52-week high for the CLVS share is $8.95, that puts it down … Will Clovis Oncology Inc. (NASDAQ: CLVS) Stock Boom Or Bust From Here? Read More »

In last trading session, Clovis Oncology Inc. (NASDAQ:CLVS) saw 7.26 million shares changing hands with its beta currently measuring 1.73. Company’s recent per share price level of $1.96 trading at $0.34 or 20.99% at ring of the bell on the day assigns it a market valuation of $260.76M. That closing price of CLVS’s stock is … Clovis Oncology Inc. (NASDAQ:CLVS) Shares Surged 2.08% In A Week – But Can It Maintain Its Gains? Read More »

Clovis (CLVS) reports narrower-than-expected loss for fourth-quarter 2021. Sales of the sole marketed drug Rubraca decline year over year due to COVID-19 impacts.

Clovis Oncology (CLVS) saw its net loss narrow ~19% in Q4 2021 compared to the prior-year period even as revenue declined.

Clovis Oncology (NASDAQ: CLVS ) reported its Q4 earnings results on Wednesday, February 23, 2022 at 08:00 AM. Here''s what investors need to know about the announcement. Earnings Clovis Oncology beat estimated earnings by 14.29%, reporting an EPS of $-0.48 versus Full story available on Benzinga.com

Clovis Oncology press release (CLVS): Q4 GAAP EPS of -$0.50.Revenue of $35.97M (-16.9% Y/Y).We have been looking forward to 2022 for a long time, which we anticipate will be the

Clovis Oncology's (CLVS) CEO Patrick Mahaffy on Q4 2021 Results - Earnings Call Transcript

Clovis Oncology (NASDAQ:CLVS) is scheduled to announce Q4 earnings results on Wednesday, February 23rd, before market open.The consensus EPS Estimate is -$0.50 (+51.0% Y/Y) and

Let us take a look at five drug/biotech companies, namely, BMRN, CLVS, TBPH, BHC and GBT, which are due to release their quarterly results on Feb 23.

In the last trading session, 2.53 million shares of the Clovis Oncology Inc. (NASDAQ:CLVS) were traded, and its beta was 1.70. Most recently the company’s share price was $1.81, and it changed around -$0.09 or -4.74% from the last close, which brings the market valuation of the company to $241.49M. CLVS currently trades at a … Clovis Oncology Inc. (NASDAQ: CLVS) Stock Forecast 2022: Profitable With Bullish Signals Read More »

BOULDER, Colo.--(BUSINESS WIRE)---- $CLVS--Clovis Oncology to Announce Fourth Quarter 2021 and Year End 2021 Financial Results and Host Webcast Conference Call

6 Top Biotech Ideas For 2022